Anixa biosciences commences treatment of fifth patient in ovarian cancer car-t clinical trial

Novel and proprietary car-t approach holds potential to be first effective car-t therapy for solid tumors san jose, calif. , may 21, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing phase 1 clinical trial of its novel chimeric antigen receptor t-cell (car-t) therapy for ovarian cancer.
CAR Ratings Summary
CAR Quant Ranking